
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Dr. Reddy's Laboratories announced the launch of its new visual identity and brand on July 1, 2015.
Dr. Reddy’s Laboratories announced the launch of its new visual identity and brand on July 1, 2015.






